TEL: 044-952-0102


Pharmaceutical Growth Markets 2013-2014

発行 EyeforPharma 商品コード 286399
出版日 ページ情報 英文 75 Pages; 18 Figures & Graphs
本日の銀行送金レート: 1USD=115.92円で換算しております。
Back to Top
医薬品の成長市場 Pharmaceutical Growth Markets 2013-2014
出版日: 2013年08月05日 ページ情報: 英文 75 Pages; 18 Figures & Graphs




第1章 イントロダクション

第2章 調査手法

第3章 製薬産業の現状

  • 医薬品投資の上位の新興市場
  • BRICに何が起こったか?
  • ロシア
    • 近年の法律の変化
  • インド
    • 新しく課せられた価格規制
    • 特許問題がインドの製薬産業に水を差す
  • 新興市場の投資を促進する主な要因

第4章 中国

  • 機会
  • 課題
  • アクセス問題
  • 医療費償還

第5章 ブラジル

  • 機会
  • 課題
  • アクセス問題
  • 医療費償還

第6章 メキシコ

  • 機会
  • 課題
  • アクセス問題
  • 医療費償還

第7章 ベネズエラ

  • 機会
  • 課題
  • アクセス問題
  • 医療費償還

第8章 インドネシア

  • 機会
  • 課題
  • アクセス問題
  • 医療費償還

第9章 タイ

  • 機会
  • アクセス問題
  • 医療費償還

第10章 産業の教訓

第11章 略語

第12章 参考資料


Understand Regional Drivers and Barriers to Take Advantage of the World's Greatest Pharma Growth Opportunities

Our primary global research reveals where the opportunities lie, how to access these markets and what approaches are and aren't working for top pharma companies in these regions.

Key questions answered - how will this report help you?

  • What are the most desirable growth markets for pharma?
  • What is it about these markets that make them so attractive to pharmaceutical companies?
  • What are the barriers to success in each market?
  • How do companies plan to grow their business in these regions over the next 5 years?
  • What are the best Sales and Marketing approaches to these unique regions?
  • What are the disruptive influences associated with the regions?
  • What are the market access strategies in each region?

Industry overview

With the continued pressure on pharmaceutical companies to generate record profits and maintain growth, companies are being forced to look beyond the developed world. The problem is not new, and it continues to be discussed within the pharmaceutical community during this extended period of austerity in the developed world - but where do companies see opportunity?

China, Mexico, and Brazil are some of the largest pharmaceutical markets by revenue in the world and yet many would still regard them as 'emerging'. Companies have clearly realized this and understood it takes more than just a treatment and basic infrastructure to be successful; in fact, certain cities within these countries are starting to resemble the major cities of the developed world. However, the difference between the wealthy developed cities and the poor rural cities is vast, and understanding these nuances is a real differentiator.

This report aims to investigate the most promising regions and also uncover insights from leading professionals on those countries which have less coverage but still represent an exciting opportunity. Through this research we discovered that executives within pharma felt the next big opportunity for growth was going to come from Venezuela, Indonesia and Thailand. Each of these markets comes from a significantly lower base than those previously mentioned, and each has their risks - but if a company is able to get it right, then the rewards could be huge.

All six of the markets we have investigated offer exciting opportunities for pharma to grow, and each requires those leading the business unit to take a different approach in order to maximize the opportunity - unfortunately, one size does not fit all. Each of these markets is different, yet it is clear that two things remain constant; the need for a strong regional development plan and a realistic pricing strategy. As in developed markets, companies need to deliver value to all stakeholders, and if they can achieve this then they will unlock the true potential these markets hold.

Who needs this report?

  • Are you a senior executive responsible for strategic decisions relating to growth markets?
  • Are you a regional office manager who wants to understand what works in other emerging markets?
  • Do you work for a multinational pharmaceutical, biotechnology, and medical device company?
  • If you answered yes to any of these questions, then the Pharmaceutical Growth Markets Report is for you.

Peer reviews - what do the experts say?

"My impression of this report is that it is diverse and it covers the most relevant emerging regions. The best part of it is the research and insight from contributors: this is what you can't find in any other papers and there is plenty of it here."

Dr. Olga Glaskova, Growth Markets Strategy & Projects, Bayer

"This study is one that has been extensively conducted by interviews of a broad range of pharma and healthcare executives from around the emerging markets. Since the majority of in-market emerging market executives are sitting in their respective countries, this report serves as a way to see through to what is happening on the other side of the globe, putting a global perspective on the wider industry."

Dr. Nara Decharin, Ph.D. General Manager - Healthcare, LF Asia

"So much has changed in the emerging markets from what we knew just two years ago. To be successful, it is important to possess the latest intelligence to fully understand the current state of the pharmaceutical market in each of the countries, in order to develop the most appropriate strategies."

Pauline Ho, Former VP Strategic Marketing, Pharmaceuticals,
Asia-Pacific and Latin America,
AuPath Consulting

Table of Contents


Industry reviews

About eyeforpharma


Index of fi gures and tables

Executive Summary







1.0 Introduction

  • 1.1 Where can product growth be expected to come from?

2.0 Methodology

  • 2.1 Industry surveys
  • 2.2 Industry Interviews

3.0 The pharma industry as it stands

  • 3.1 Top emerging markets for pharma investments
  • 3.2 Whatever happened to BRIC?
  • 3.3 Russia.
  • 3.3.1 Recent legislative changes
  • 3.4 India.
    • 3.4.1 New pricing regulations imposed
    • 3.4.2 Patenting issues cast a chill over India’s pharma industry
  • 3.6 Key factors driving emerging market investments

4.0 China

  • 4.0.1 Healthcare a government priority
  • 4.0.2 IT development and social networking key
  • 4.0.3 Pharma tapping into traditional medicine
  • 4.1 Opportunities
    • 4.1.1 Making a virtue out of a necessity
  • 4.2 Challenges
    • 4.2.1 Succeeding though human talent
    • 4.2.2 A changing patenting climate
  • 4.3 Access issues
  • 4.4 Reimbursement
    • 4.4.1 A role for pharmacoeconomic studies
    • 4.4.2 Price cuts
    • 4.4.3 Adding value
    • 4.4.4 Multi-payer schemes

5.0 Brazil

  • 5.1 Opportunities
    • 5.1.1 Generics Act coming to fruition
    • 5.1.2 Rising disease prevalence
    • 5.1.3 Partnering for success
    • 5.1.4 Private market growth
  • 5.2 Challenges
    • 5.2.1 Regulations
    • 5.2.2 Poor infrastructures hinder pharma operations
    • 5.2.3 Illegal pharma production
  • 5.3 Access issues
  • 5.4 Reimbursement
    • 5.4.1 Squeeze of prices 4

6.0 Mexico

  • 6.0.1 Universal healthcare coverage a goal, private-sector spending on rise
    • 6.0.2 Branded products gaining ground
  • 6.1 Opportunities
    • 6.1.1 Specializing in niche areas the main focus
  • 6.2 Challenges
    • 6.2.1 Mexican companies take a bullish stance
    • 6.2.2 Government out to drive down costs
  • 6.3 Access issues
  • 6.4 Reimbursement

7.0 Venezuela

  • 7.1 Opportunities
    • 7.1.1 Careful targeting crucial
  • 7.2 Challenges
    • 7.2.1 Currency controls the main challenge
    • 7.2.2 Price controls an additional burden
  • 7.3 Access issues
  • 7.4 Reimbursement

8.0 Indonesia

  • 8.1 Opportunities
    • 8.1.1 Roll-out of universal healthcare
    • 8.1.2 Clear win-win for pharma-insurer partnerships
  • 8.2 Challenges
    • 8.2.1 Weak infrastructure
  • 8.3 Access issues
  • 8.4 Reimbursement

9.0 Thailand

  • 9.1 Opportunities
    • 9.1.1 Targeting physicians
    • 9.2.3 e-marketing still in its infancy
  • 9.3 Access issues
  • 9.4 Reimbursement
    • 9.4.1 Universal Coverage Scheme
    • 9.4.2 Civil Servants' Medical Benefi t Scheme
    • 9.4.3 Social Security Scheme

10.0 Industry learning's

11.0 Abbreviations

12.0 References

Back to Top